VistaGen Therapeutics
VTGN
106 hedge funds and large institutions have $269M invested in VistaGen Therapeutics in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 11 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
2% more funds holding
Funds holding: 104 → 106 (+2)
0.03% more ownership
Funds ownership: 2.27% → 2.31% (+0.03%)
25% less capital invested
Capital invested by funds: $360M → $269M (-$91.2M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
93% less call options, than puts
Call options by funds: $73K | Put options by funds: $1.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$7.25M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.34M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$3.26M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.62M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$2.31M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$2.18M |
| 3 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.74M |
| 4 |
Two Sigma Investments
New York
|
-$1.4M |
| 5 |
Millennium Management
New York
|
-$943K |
VTGN Hedge Fund Activity: Q4 2021 in Review
106 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2021, worth a combined $269M — down 25% from $360M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new VTGN positions and 11 closed out — a net gain of 2 holders — while 39 added to existing stakes and 29 trimmed.
The largest buyer was Commodore Capital, adding an estimated $7.25M. The largest seller was EAM Investors, exiting entirely with an estimated $2.31M sold.
- 106 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2021, up from 104 in Q3 2021.
- Funds reported $269M of VistaGen Therapeutics stock for Q4 2021, down 25% quarter-over-quarter.
- 13 funds opened new VistaGen Therapeutics positions in Q4 2021 and 11 closed out, a net change of +2 holders.
- The largest VistaGen Therapeutics buyer in Q4 2021 was Commodore Capital, an estimated $7.25M added.
- The largest VistaGen Therapeutics seller in Q4 2021 was EAM Investors, an estimated $2.31M sold.
Based on aggregated 13F filings for Q4 2021.